Newport, RI - August 15, 2021 - An article appearing recently in the online issue of the journal Nature described a single-cell study that shows how some rare cancer cells can proliferate under drug treatment and could aid scientists in developing better therapeutics to prevent recurrence of cancer.
The lead author of the study is Hope Funds for Cancer Research Fellow Yaara Oren, Ph.D. at The Broad Institute and Harvard Medical School, in the laboratory of Joan Brugge, Ph.D. The findings are described in a news story by the Broad Institute. Click here to read the article Broad Release.
"Hope Funds is delighted to learn of of these important findings shared by Dr. Oren and a distinguished team of scientists from Harvard Medical School and the Broad Institute," said Leah Rush Cann, Chair of the Hope Funds Executive Committee.
Dr. Oren is the 2020-21 Hope Funds Grillo-Marxuach Family Fellow. San Diego residents Antonio Grillo-Lopez and Maria S. Grillo created this named gift with Hope Funds for Cancer Research on behalf of the Grillo-Marxuach Family, to fund the final year of Dr. Oren's postdoctoral fellowship.
“This work could not have been done without Hope Funds’ support,” said Dr. Oren.
Hope Funds was established with the immediate goal of supporting important cancer research in the most challenging and understudied cancers on the premise that funding outstanding post-doctoral researchers was the most productive and cost effective way to achieve that goal, a hypothesis Mrs. Cann said has proven correct.
"What we discovered along the way was that the Hope Funds fellowships have become a critical bridge for outstanding scientists like Dr. Oren to remain focused on research at a time when research is extremely scarce," said Mrs. Cann. "The fellowships not only support three years of research, but also help facilitate a lifetime of collaborations and discoveries."
About Yaara Oren, Ph.D.
Dr. Oren is at The Broad Institute and Harvard Medical School, in the laboratory of Joan Brugge, Ph.D. Despite a good initial response to chemotherapy, ovarian cancer comes back in the majority of patients and leads to death within five years of diagnosis. When the cancer first comes back, it may still be responsive to chemotherapy in many cases before eventually becoming drug resistant. Several mechanisms have been suggested to contribute to the disease coming back but we don't know exactly how and how much each of these mechanisms impact the process. In Dr. Oren's work, she is trying to uncover and understand the factors that contribute to the re-emergence of ovarian cancer that is still responsive to chemotherapy, by using a new method that allow her to trace how individual single cells respond to multiple rounds of chemotherapy. This novel tracing technique makes it possible to study how an ovarian cancer cell's past behavior and pedigree affect its ability to survive drug treatment. Her work combines several techniques including microscopy, sequencing, mathematical modeling and patient data to expose not only what makes cells resistant to initial treatment but also what effects their ability to regenerate the tumor. We believe that this unique methodology will help identify which genes and cellular pathways are important for relapse. The insights gained from this integrated approach will help devise new drug therapies that delay or even prevent the emergence of resistant ovarian cancer. Dr. Oren received her B.A. and Ph.D. from Tel-Aviv University.
About Nature
Nature is the foremost international weekly scientific journal in the world and is the flagship journal for Nature Portfolio. It publishes the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature publishes landmark papers, award winning news, leading comment and expert opinion on important, topical scientific news and events that enable readers to share the latest discoveries in science and evolve the discussion amongst the global scientific community.
About Hope Funds for Cancer Research
Hope Funds for Cancer Research was formed in 2006 to establish a funding vehicle that would take a rational scientific, medical, and investment approach to making grants for the most innovative and promising research efforts to address the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, renal and ovarian cancers, as well as rare leukemias, lymphomas and MDS. These cancers are insidiously aggressive illnesses that kill most of their victims within months, even with aggressive chemotherapy. The Trustees of the Hope Funds for Cancer Research believe that funding young, innovative researchers will lead to breakthroughs in these areas and increase life expectancy for those with these types of cancers. The Hope Funds for Cancer Research is a 509 (a)(1) charity under 501(c)(3) of the Internal Revenue Service's code.
For additional information about the organization, please visit www.hope-funds.org or call (401) 847-3286.
Hope Funds for Cancer Research: Advancing innovative research in understudied cancers
Hope Funds for Cancer Research is an independent and unaffiliated non-profit organization
8/15/21- 8